Biomimetic particles as therapeutics

Trends in Biotechnology

Volumn 33, Issue 9, 2015, Pages 514-524

  Meyer, Randall A ^a   Sunshine, Joel C ^a   Green, Jordan J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biomaterial; Biomimetic; Drug delivery; Micro nanoparticle

Indexed keywords

BIOMATERIALS; BIOMIMETICS; CONTROLLED DRUG DELIVERY; CYTOLOGY; DRUG DELIVERY; MEMBRANE TECHNOLOGY; VIRUSES;

ARTIFICIAL CELL MEMBRANE; BIOMIMETIC PARTICLE; BIOMIMETIC SURFACES; CONTROL OF SIZE; MATERIAL CONSISTENCY; MICRO PARTICLES; MICRO/NANOPARTICLE; THERAPEUTIC PARTICLES;

BIOMIMETIC PROCESSES;

BIOMIMETIC MATERIAL; DOCETAXEL; DOXORUBICIN; INTERLEUKIN 2 RECEPTOR ALPHA; NANOPARTICLE; POLYSTYRENE; TRANSFERRIN RECEPTOR; VACCINE;

ARTIFICIAL MEMBRANE; CELL MEMBRANE; DENDRITIC CELL; LIPID BILAYER; MACROPHAGE; PARTICLE SIZE; PRIORITY JOURNAL; REVIEW; ANIMAL; BIOMIMETICS; CHEMISTRY; HUMAN; MOUSE; NANOTECHNOLOGY; ULTRASTRUCTURE;

ANIMALS; BIOMIMETIC MATERIALS; BIOMIMETICS; HUMANS; MICE; NANOPARTICLES; NANOTECHNOLOGY;

EID: 84940450222     PISSN: 01677799     EISSN: 18793096     Source Type: Journal    
DOI: 10.1016/j.tibtech.2015.07.001     Document Type: Review

References (103)

1. Liu H., et al. Structure-based programming of lymph-node targeting in molecular vaccines. Nature 2014, 507:519-522.
2. Yoo J.W., et al. Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nat. Rev. Drug Discov. 2011, 10:521-535.
3. Yan F., et al. Apoferritin protein cages: a novel drug nanocarrier for photodynamic therapy. Chem. Commun. (Camb.) 2008, 38:4579-4581.
4. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J. Control. Release 2008, 132:171-183.
5. Mescher M. Surface contact requirements for activation of cytotoxic T lymphocytes. J. Immunol. 1992, 149:2402-2405.
6. Shalaby W.S., et al. Absorbable microparticulate cation exchanger for immunotherapeutic delivery. J. Biomed. Mater. Res. B: Appl. Biomater. 2004, 69:173-182.
7. Giannoni F., et al. Clustering of T cell ligands on artificial APC membranes influences T cell activation and protein kinase C θ translocation to the T cell plasma membrane. J. Immunol. 2005, 174:3204-3211.
8. Steenblock E.R., Fahmy T.M. A comprehensive platform for ex vivo T-cell expansion based on biodegradable polymeric artificial antigen-presenting cells. Mol. Ther. 2008, 16:765-772.
9. Perica K., et al. Linking form to function: biophysical aspects of artificial antigen presenting cell design. Biochim. Biophys. Acta 2015, 1853:781-790.
10. Alarcon B., et al. The immunological synapse: a cause or consequence of T-cell receptor triggering?. Immunology 2011, 133:420-425.
11. Prakken B., et al. Artificial antigen-presenting cells as a tool to exploit the immunesynapse. Nat. Med. 2000, 6:1406-1410.
12. Sunshine J.C., Green J.J. Nanoengineering approaches to the design of artificial antigen-presenting cells. Nanomedicine 2013, 8:1173-1189.
13. Perica K., et al. Nanoscale artificial antigen presenting cells for T cell immunotherapy. Nanomedicine 2014, 10:119-129.
14. Perica K., et al. Magnetic field-induced T cell receptor clustering by nanoparticles enhances T cell activation and stimulates antitumor activity. ACS Nano 2014, 8:2252-2260.
15. Gratton S.E., et al. The effect of particle design on cellular internalization pathways. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:11613-11618.
16. Zhao F., et al. Cellular uptake, intracellular trafficking, and cytotoxicity of nanomaterials. Small 2011, 7:1322-1337.
17. Fenner F.J., et al. The Biology of Animal Viruses 2013, Elsevier.
18. Oyewumi M.O., et al. Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev. Vaccines 2010, 9:1095-1107.
19. Foged C., et al. Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. Int. J. Pharm. 2005, 298:315-322.
20. Vallhov H., et al. Mesoporous silica particles induce size dependent effects on human dendritic cells. Nano Lett. 2007, 7:3576-3582.
21. Manolova V. (2008) Nanoparticles target distinct dendritic cell populations according to their size. Eur. J. Immunol. 2008, 38:1404-1413.
22. Peer D., et al. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007, 2:751-760.
23. Haghgooie R., et al. Non-spherical hydrogel microparticles. Macromol. Rapid Commun. 2010, 31:128-134.
24. Merkel T.J., et al. Using mechanobiological mimicry of red blood cells to extend circulation times of hydrogel microparticles. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:586-591.
25. Merkel T.J., et al. The effect of particle size on the biodistribution of low-modulus hydrogel PRINT particles. J. Control. Release 2012, 162:37-44.
26. Doshi N., et al. Red blood cell-mimicking synthetic biomaterial particles. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:21495-21499.
27. Noad R., Roy P. Virus-like particles as immunogens. Trends Microbiol. 2003, 11:438-444.
28. Rosenthal J.A., et al. Pathogen-like particles: biomimetic vaccine carriers engineered at the nanoscale. Curr. Opin. Biotechnol. 2014, 28:51-58.
29. Roldão A., et al. Virus-like particles in vaccine development. Expert Rev. Vaccines 2010, 9:1149-1176.
30. Verma A., Stellacci F. Effect of surface properties on nanoparticle-cell interactions. Small 2010, 6:12-21.
31. Cho E.C., et al. Understanding the role of surface charges in cellular adsorption versus internalization by selectively removing gold nanoparticles on the cell surface with a I2/KI etchant. Nano Lett. 2009, 9:1080-1084.
32. Fadel T.R. Enhanced cellular activation with single walled carbon nanotube bundles presenting antibody stimuli. Nano Lett. 2008, 8:2070-2076.
33. Fadel T.R., et al. A carbon nanotube-polymer composite for T-cell therapy. Nat. Nanotechnol. 2014, 9:639-647.
34. Fletcher D.A., Mullins R.D. Cell mechanics and the cytoskeleton. Nature 2010, 463:485-492.
35. Geng Y., et al. Shape effects of filaments versus spherical particles in flow and drug delivery. Nat. Nanotechnol. 2007, 2:249-255.
36. Ho C., et al. Preparation of monodisperse ellipsoidal polystyrene particles. Colloid Polym. Sci. 1993, 271:469-479.
37. Champion J.A., et al. Making polymeric micro- and nanoparticles of complex shapes. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:11901-11904.
38. Meyer R.A., et al. An automated multidimensional thin film stretching device for the generation of anisotropic polymeric micro- and nanoparticles. J. Biomed. Mater. Res. A 2015, 103:2747-2757.
39. Rolland J.P., et al. Direct fabrication and harvesting of monodisperse, shape-specific nanobiomaterials. J. Am. Chem. Soc. 2005, 127:10096-10100.
40. Wang Y., et al. Generation of a library of particles having controlled sizes and shapes via the mechanical elongation of master templates. Langmuir 2011, 27:524-528.
41. Morton S.W., et al. Scalable manufacture of built-to-order nanomedicine: spray-assisted layer-by-layer functionalization of PRINT nanoparticles. Adv. Mater. 2013, 25:4707-4713.
42. Luo G., et al. Controllable preparation of particles with microfluidics. Particuology 2011, 9:545-558.
43. Meyer R.A., Green J.J. Shaping the future of nanomedicine: anisotropy in polymeric nanoparticle design. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2015, Published online May 15, 2015. 10.1002/wnan.1348.
44. Oelke M., et al. Artificial antigen-presenting cells: artificial solutions for real diseases. Trends Mol. Med. 2005, 11:412-420.
45. + T cell activation by artificial antigen presenting cells. Biomaterials 2014, 35:269-277.
46. Meyer R.A., et al. Biodegradable nanoellipsoidal artificial antigen presenting cells for antigen specific T-cell activation. Small 2014, 11:1519-1525.
47. Champion J.A., Mitragotri S. Shape induced inhibition of phagocytosis of polymer particles. Pharm. Res. 2009, 26:244-249.
48. Sharma G., et al. Polymer particle shape independently influences binding and internalization by macrophages. J. Control. Release 2010, 147:408-412.
49. Florez L., et al. How shape influences uptake: interactions of anisotropic polymer nanoparticles and human mesenchymal stem cells. Small 2012, 8:2222-2230.
50. Champion J.A., Mitragotri S. Role of target geometry in phagocytosis. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:4930-4934.
51. Agarwal R., et al. Mammalian cells preferentially internalize hydrogel nanodiscs over nanorods and use shape-specific uptake mechanisms. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:17247-17252.
52. Barua S., et al. Particle shape enhances specificity of antibody-displaying nanoparticles. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:3270-3275.
53. Kolhar P., et al. Using shape effects to target antibody-coated nanoparticles to lung and brain endothelium. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:10753-10758.
54. Toy R., et al. Shaping cancer nanomedicine: the effect of particle shape on the in vivo journey of nanoparticles. Nanomedicine 2014, 9:121-134.
55. Hasan W., et al. Delivery of multiple siRNAs using lipid-coated PLGA nanoparticles for treatment of prostate cancer. Nano Lett. 2012, 12:287-292.
56. Xu J., et al. RNA replicon delivery via lipid-complexed PRINT protein particles. Mol. Pharm. 2013, 10:3366-3374.
57. Chu K.S., et al. Plasma, tumor and tissue pharmacokinetics of docetaxel delivered via nanoparticles of different sizes and shapes in mice bearing SKOV-3 human ovarian carcinoma xenograft. Nanomedicine 2013, 9:686-693.
58. Chu K.S., et al. Particle replication in nonwetting templates nanoparticles with tumor selective alkyl silyl ether docetaxel prodrug reduces toxicity. Nano Lett. 2014, 14:1472-1476.
59. Chu K.S., et al. Nanoparticle drug loading as a design parameter to improve docetaxel pharmacokinetics and efficacy. Biomaterials 2013, 34:8424-8429.
60. Jiang X., et al. String-like micellar nanoparticles formed by complexation of PEG-b-PPA and plasmid DNA and their transfection efficiency. Pharm. Res. 2011, 28:1317-1327.
61. Jiang X., et al. Plasmid-templated shape control of condensed DNA-block copolymer nanoparticles. Adv. Mater. 2013, 25:227-232.
62. Karagoz B., et al. Polymerization-induced self-assembly (PISA) - control over the morphology of nanoparticles for drug delivery applications. Polym. Chem. 2014, 5:350.
63. Valitutti S., et al. The space and time frames of T cell activation at the immunological synapse. FEBS Lett. 2010, 584:4851-4857.
64. Peña J.R., et al. Localized delivery of mechano-growth factor E-domain peptide via polymeric microstructures improves cardiac function following myocardial infarction. Biomaterials 2015, 46:26-34.
65. Dyson S., et al. Evaluation of PLGA nanoparticles carrying leukaemia inhibitory factor for stromal-like support of rat fetal dopaminergic cells. J. Nanomater. Mol. Nanotechnol. 2014, Published online June 20, 2014. 10.4172/2324-8777.S2-003.
66. Zhao X., et al. Directed cell migration via chemoattractants released from degradable microspheres. Biomaterials 2005, 26:5048-5063.
67. Popova T.G., et al. Chemokine-releasing nanoparticles for manipulation of the lymph node microenvironment. Nanomaterials 2015, 5:298-320.
68. Huang Y-C., Liu T-J. Mobilization of mesenchymal stem cells by stromal cell-derived factor-1 released from chitosan/tripolyphosphate/fucoidan nanoparticles. Acta Biomater. 2012, 8:1048-1056.
69. Steenblock E.R., et al. An artificial antigen-presenting cell with paracrine delivery of IL-2 impacts the magnitude and direction of the T cell response. J. Biol. Chem. 2011, 286:34883-34892.
70. Lai S.K., et al. Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:1482-1487.
71. Gref R., et al. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf. B: Biointerfaces 2000, 18:301-313.
72. Mout R., et al. Surface functionalization of nanoparticles for nanomedicine. Chem. Soc. Rev. 2012, 41:2539-2544.
73. Rodriguez P.L., et al. Minimal "self" peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. Science 2013, 339:971-975.
74. Sengupta S., et al. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 2005, 436:568-572.
75. Tanaka M., Sackmann E. Polymer-supported membranes as models of the cell surface. Nature 2005, 437:656-663.
76. Roder F., et al. Rapid transfer of transmembrane proteins for single molecule dimerization assays in polymer-supported membranes. ACS Chem. Biol. 2014, 9:2479-2484.
77. Roder F., et al. Spatial organization of lipid phases in micropatterned polymer-supported membranes. J. Am. Chem. Soc. 2013, 135:1189-1192.
78. Waichman S., et al. Diffusion and interaction dynamics of individual membrane protein complexes confined in micropatterned polymer-supported membranes. Small 2013, 9:570-577.
79. Roder F., et al. Reconstitution of membrane proteins into polymer-supported membranes for probing diffusion and interactions by single molecule techniques. Anal. Chem. 2011, 83:6792-6799.
80. Grakoui A., et al. The immunological synapse: a molecular machine controlling T cell activation. Science 1999, 285:221-227.
81. Chan P.Y., et al. Influence of receptor lateral mobility on adhesion strengthening between membranes containing Lfa-3 and Cd2. J. Cell Biol. 1991, 115:245-255.
82. Groves J.T., Dustin M.L. Supported planar bilayers in studies on immune cell adhesion and communication. J. Immunol. Methods 2003, 278:19-32.
83. Sackmann E. Supported membranes: scientific and practical applications. Science 1996, 271:43-48.
84. Loidl-Stahlhofen A., et al. The thermodynamic control of protein binding to lipid bilayers for protein chromatography. Nat. Biotechnol. 1996, 14:999-1002.
85. Galneder R., et al. Microelectrophoresis of a bilayer-coated silica bead in an optical trap: application to enzymology. Biophys. J. 2001, 80:2298-2309.
86. Jacobson B.S., Branton D. Plasma-membrane - rapid isolation and exposure of cytoplasmic surface by use of positively charged beads. Science 1977, 195:302-304.
87. Cohen C.M., et al. Membrane isolation on polylysine-coated beads - plasma-membrane from HeLa-cells. J. Cell Biol. 1977, 75:119-134.
88. Kaufmann S., Tanaka M. Cell adhesion onto highly curved surfaces: one-step immobilization of human erythrocyte membranes on silica beads. Chemphyschem 2003, 4:699-704.
89. Liu J., et al. Porous nanoparticle supported lipid bilayers (protocells) as delivery vehicles. J. Am. Chem. Soc. 2009, 131:1354-1355.
90. Liu J.W., et al. Silica nanoparticle supported lipid bilayers for gene delivery. Chem. Commun. (Camb.) 2009, 34:5100-5102.
91. Liu J.W., et al. Electrostatically mediated liposome fusion and lipid exchange with a nanoparticle-supported bilayer for control of surface charge, drug containment, and delivery. J. Am. Chem. Soc. 2009, 131:7567-7569.
92. Ashley C.E., et al. The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers. Nat. Mater. 2011, 10:389-397.
93. Patel P.D., et al. Drug loaded erythrocytes: as novel drug delivery system. Curr. Pharm. Des. 2008, 14:63-70.
94. Zarrin A., et al. Carrier erythrocytes: recent advances, present status, current trends and future horizons. Expert Opin. Drug Deliv. 2014, 11:433-447.
95. Muzykantov V.R. Drug delivery by red blood cells: vascular carriers designed by mother nature. Expert Opin. Drug Deliv. 2010, 7:403-427.
96. Hu C.M., et al. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:10980-10985.
97. Hu C.M., et al. 'Marker-of-self' functionalization of nanoscale particles through a top-down cellular membrane coating approach. Nanoscale 2013, 5:2664-2668.
98. Hu C.M., et al. A biomimetic nanosponge that absorbs pore-forming toxins. Nat. Nanotechnol. 2013, 8:336-340.
99. Hu C.M., et al. Nanoparticle-detained toxins for safe and effective vaccination. Nat. Nanotechnol. 2013, 8:933-938.
100. Parodi A., et al. Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat. Nanotechnol. 2013, 8:61-68.
101. Menter D.G., et al. Role of platelet membrane in enhancement of tumor-cell adhesion to endothelial-cell extracellular-matrix. Cancer Res. 1987, 47:6751-6762.
102. Furman N.E.T., et al. Reconstructed stem cell nanoghosts: a natural tumor targeting platform. Nano Lett. 2013, 13:3248-3255.
103. Fang R.H., et al. Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery. Nano Lett. 2014, 14:2181-2188.